Tempus AI (TEM) announced the acquisition of Paige, an AI company specializing in digital pathology. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowing researchers and pathologists to better detect cancer, which enables care teams to make more precise and informed treatment decisions. Tempus is acquiring Paige for $81.25M, which is being paid predominantly in Tempus common stock, as well as Tempus’ assumption of Paige’s remaining commitment under its existing Microsoft Azure cloud services agreement.
Claim 30% Off TipRanks
Trade TEM with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- tempus AI Inc Class A call volume above normal and directionally bullish
- Tempus AI price target raised to $85 from $75 at BTIG
- Tempus AI, Inc.: Strong Growth Prospects and Strategic Expansion Justify Buy Rating
- Mixed options sentiment in tempus AI Inc Class A with shares down 6.85%
- Mixed options sentiment in tempus AI Inc Class A with shares up 3.58%